In current clinical practice, one of the challenges is accurately determining whether chemotherapy is necessary for a patient with ER-positive human epidermal growth factor receptor 2 (HER2)-negative BC in an adjuvant setting; the decision is based on an assessment of risk factors such as histopathology, tumour size, and the number of lymph nodes involved. Here, ERBB2 is linked to neoplasm.